BSIP/Common Visuals Team by means of Getty
Aduhelm, regarded generically as aducanumab, is the very first drug to in fact have an affect on the fundamental disease method connected with Alzheimer’s. Still gross sales have been confined, and the drug is reaching quite handful of people — at minimum so far. It is high-priced, risky and most likely carrying out small to increase patients’ lives. NPR science correspondent Jon Hamilton explains why physicians and sufferers aren’t thrilled about the new drug and what it could suggest for long term Alzheimer’s medicine.
You can generally arrive at the clearly show by emailing [email protected]
This episode was edited by Sara Sarasohn, produced by Rebecca Ramirez and fact-checked by Margaret Cirino. Neil Tevault was the audio engineer.